1
|
Frank E, Cailleret M, Nelep C, Fragner P, Polentes J, Herardot E, El Kassar L, Giraud-Triboult K, Monville C, Ben M'Barek K. Semi-automated optimized method to isolate CRISPR/Cas9 edited human pluripotent stem cell clones. Stem Cell Res Ther 2023; 14:110. [PMID: 37106426 PMCID: PMC10142500 DOI: 10.1186/s13287-023-03327-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 04/04/2023] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND CRISPR/Cas9 editing systems are currently used to generate mutations in a particular gene to mimic a genetic disorder in vitro. Such "disease in a dish" models based on human pluripotent stem cells (hPSCs) offer the opportunity to have access to virtually all cell types of the human body. However, the generation of mutated hPSCs remains fastidious. Current CRISPR/Cas9 editing approaches lead to a mixed cell population containing simultaneously non-edited and a variety of edited cells. These edited hPSCs need therefore to be isolated through manual dilution cloning, which is time-consuming, labor intensive and tedious. METHODS Following CRISPR/Cas9 edition, we obtained a mixed cell population with various edited cells. We then used a semi-automated robotic platform to isolate single cell-derived clones. RESULTS We optimized CRISPR/Cas9 editing to knock out a representative gene and developed a semi-automated method for the clonal isolation of edited hPSCs. This method is faster and more reliable than current manual approaches. CONCLUSIONS This novel method of hPSC clonal isolation will greatly improve and upscale the generation of edited hPSCs required for downstream applications including disease modeling and drug screening.
Collapse
Affiliation(s)
- Elie Frank
- INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic Diseases, 91100, Corbeil-Essonnes, France
- U861, I-Stem, AFM, Université Paris-Saclay, Université d'Evry, 91100, Corbeil-Essonnes, France
| | - Michel Cailleret
- INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic Diseases, 91100, Corbeil-Essonnes, France
- U861, I-Stem, AFM, Université Paris-Saclay, Université d'Evry, 91100, Corbeil-Essonnes, France
| | | | - Pascal Fragner
- INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic Diseases, 91100, Corbeil-Essonnes, France
- U861, I-Stem, AFM, Université Paris-Saclay, Université d'Evry, 91100, Corbeil-Essonnes, France
- CECS, Centre d'étude des cellules souches, 91100, Corbeil-Essonnes, France
| | - Jérome Polentes
- INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic Diseases, 91100, Corbeil-Essonnes, France
- U861, I-Stem, AFM, Université Paris-Saclay, Université d'Evry, 91100, Corbeil-Essonnes, France
- CECS, Centre d'étude des cellules souches, 91100, Corbeil-Essonnes, France
| | - Elise Herardot
- INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic Diseases, 91100, Corbeil-Essonnes, France
- U861, I-Stem, AFM, Université Paris-Saclay, Université d'Evry, 91100, Corbeil-Essonnes, France
| | - Lina El Kassar
- INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic Diseases, 91100, Corbeil-Essonnes, France
- U861, I-Stem, AFM, Université Paris-Saclay, Université d'Evry, 91100, Corbeil-Essonnes, France
- CECS, Centre d'étude des cellules souches, 91100, Corbeil-Essonnes, France
| | - Karine Giraud-Triboult
- INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic Diseases, 91100, Corbeil-Essonnes, France
- U861, I-Stem, AFM, Université Paris-Saclay, Université d'Evry, 91100, Corbeil-Essonnes, France
- CECS, Centre d'étude des cellules souches, 91100, Corbeil-Essonnes, France
| | - Christelle Monville
- INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic Diseases, 91100, Corbeil-Essonnes, France.
- U861, I-Stem, AFM, Université Paris-Saclay, Université d'Evry, 91100, Corbeil-Essonnes, France.
| | - Karim Ben M'Barek
- INSERM U861, I-Stem, AFM, Institute for Stem cell Therapy and Exploration of Monogenic Diseases, 91100, Corbeil-Essonnes, France.
- U861, I-Stem, AFM, Université Paris-Saclay, Université d'Evry, 91100, Corbeil-Essonnes, France.
- CECS, Centre d'étude des cellules souches, 91100, Corbeil-Essonnes, France.
| |
Collapse
|
2
|
Nikitina TV, Lebedev IN. Stem Cell-Based Trophoblast Models to Unravel the Genetic Causes of Human Miscarriages. Cells 2022; 11:1923. [PMID: 35741051 PMCID: PMC9221414 DOI: 10.3390/cells11121923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Revised: 06/10/2022] [Accepted: 06/12/2022] [Indexed: 02/01/2023] Open
Abstract
Miscarriage affects approximately 15% of clinically recognized pregnancies, and 1-3% of couples experience pregnancy loss recurrently. Approximately 50-60% of miscarriages result from chromosomal abnormalities, whereas up to 60% of euploid recurrent abortions harbor variants in candidate genes. The growing number of detected genetic variants requires an investigation into their role in adverse pregnancy outcomes. Since placental defects are the main cause of first-trimester miscarriages, the purpose of this review is to provide a survey of state-of-the-art human in vitro trophoblast models that can be used for the functional assessment of specific abnormalities/variants implicated in pregnancy loss. Since 2018, when primary human trophoblast stem cells were first derived, there has been rapid growth in models of trophoblast lineage. It has been found that a proper balance between self-renewal and differentiation in trophoblast progenitors is crucial for the maintenance of pregnancy. Different responses to aneuploidy have been shown in human embryonic and extra-embryonic lineages. Stem cell-based models provide a powerful tool to explore the effect of a specific aneuploidy/variant on the fetus through placental development, which is important, from a clinical point of view, for deciding on the suitability of embryos for transfer after preimplantation genetic testing for aneuploidy.
Collapse
Affiliation(s)
- Tatiana V. Nikitina
- Research Institute of Medical Genetics, Tomsk National Research Medical Center, 634050 Tomsk, Russia;
| | | |
Collapse
|